A new investigational antibody is an effective treatment for patients who suffer from the inflammatory bowel diseases Crohn’s disease and colitis when other treatments fail, a study has found.
The international GEMINI studies, led by Western University’s Dr. Brian Feagan, found that the antibody vedolizumab is effective for patients with ulcerative colitis (UC) and Crohn’s disease (CD), and may be a viable treatment for patients whose current treatments are not working.
“This was really an important finding for patients who are failing these medications and are suffering from inflammatory bowel disease,” Feagan told CTV News. “It’ll give them another option.”
UC and CD are two of the most common forms of inflammatory bowel disease, affecting more than four million people around the world. Symptoms of the diseases can include bleeding, diarrhea, fatigue, weight loss and anemia. Canada has one of the highest rates of IBD in the world.